**Name of Journal:** *World Journal of Cardiology*

**Manuscript NO:** 80407

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Cohort Study***

**Utility of short-term telemetry heart rhythm monitoring and CHA2DS2-VASc stratification in patients presenting with suspected cerebrovascular accident**

Bhuiya T *et al*. Utility of short-term telemetry monitoring

Tanzim Bhuiya, Sherif Roman, Taner Aydin, Bhakti Patel, Roman Zeltser, Amgad N Makaryus

**Tanzim Bhuiya, Taner Aydin, Bhakti Patel, Roman Zeltser, Amgad N Makaryus,** Department of Cardiology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY 11553, United States

**Sherif Roman,** Department of Cardiology, St. Joseph’s University Medical Center, Paterson, NJ 07503, United States

**Roman Zeltser, Amgad N Makaryus,** Department of Cardiology, Nassau University Medical Center, East Meadow, NY 11554, United States

**Author contributions:** Aydin T, Zeltser R, Makaryus AN performed the research; Bhuiya T and Zeltser R performed the statistical analyses in the paper; Zeltser R and Makaryus AN designed the research and contributed to the analysis; Bhuiya T, Roman S, Aydin T, Patel B, Makaryus AN, wrote the paper; Zeltser R, and Makaryus AN supervised the report.

**Corresponding author: Amgad N Makaryus, MD, FACC, Professor,** **Chairman,** Department of Cardiology, Nassau University Medical Center, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, 2201 Hempstead Turnpike, East Meadow, NY 11554, United States. amakaryu@numc.edu

**Received:** September 26, 2022

**Revised:** January 10, 2023

**Accepted:** February 7, 2023

**Published online:**

**Abstract**

BACKGROUND

Inpatient telemetry heart rhythm monitoring overuse has been linked to higher healthcare costs.

AIM

To evaluate if CHA2DS2-VASc score could be used to indicate if a patient admitted with possible cerebrovascular accident (CVA) or transient ischemic attack (TIA) requires inpatient telemetry monitoring.

METHODS

A total of 257 patients presenting with CVA or TIA and placed on telemetry monitoring were analyzed retrospectively. We investigated the utility of telemetry monitoring to diagnose atrial fibrillation/flutter and the CHA2DS2-VASc scoring tool to stratify the risk of having CVA/TIA in these patients.

RESULTS

In our study population, 63 (24.5%) of the patients with CVA/TIA and telemetry monitoring were determined to have no ischemic neurologic event. Of the 194 (75.5) patients that had a confirmed CVA/TIA, only 6 (2.3%) had an arrhythmia detected during their inpatient telemetry monitoring period. Individuals with a confirmed CVA/TIA had a statistically significant higher CHA2DS2-VASc score compared to individuals without an ischemic event (3.59 *vs* 2.61, *P* < 0.001).

CONCLUSION

Given the low percentage of inpatient arrhythmias identified, further research should focus on discretionary use of inpatient telemetry on higher risk patients to diagnose the arrhythmias commonly leading to CVA/TIA. A prospective study assessing event rate of CVA/TIA in patients with higher CHA2DS2-VASc score should be performed to validate the CHA2DS2-VASc score as a possible risk stratifying tool for patients at risk for CVA/TIA.

**Key Words:** Telemetry monitoring; CHA2DS2-VASc score; Arrhythmia; Atrial fibrillation

Bhuiya T, Roman S, Aydin T, Patel B, Zeltser R, Makaryus AN. Utility of short-term telemetry heart rhythm monitoring and CHA₂DS₂-VASc stratification in patients presenting with suspected cerebrovascular accident. *World J Cardiol* 2023; In press

**Core Tip:** Inpatient telemetry monitoring can be a costly resource in hospitals. Inappropriate use of this clinical tool only increases burgeoning healthcare costs both to the patient and the hospital. Atrial fibrillation is a risk factor for stroke which is why telemetry is indicated for 24-48 h after a cerebrovascular accident. However, telemetry for all patients for this short period of time can be non-diagnostic. Our study shows telemetry can be better utilized in patients with higher risk factors for atrial fibrillation as seen with higher CHA2DS2-VASc scores, and this stratification of telemetry monitoring may allow appropriate allocation and use for patients in whom benefit will be derived.

**INTRODUCTION**

Non-intensive-care inpatient telemetry monitoring is a widely used observation tool in cardiovascular medicine. The use of non-intensive-care telemetry is widely utilized in the setting of suspected cerebrovascular accident (CVA) or transient ischemic attack (TIA)[1]. One of the most common causes of CVA/TIA is atrial fibrillation (AFib). The 2018 stroke guidelines states that cardiac monitoring is recommended for atrial fibrillation as part of in-hospital secondary prevention. Cardiac monitoring should be performed for at least the first 24 h[2]. Telemetry monitoring is utilized in these cases to assess whether undiagnosed atrial fibrillation was the cause of their ischemic event. Past studies have demonstrated that the use of telemetry inpatient post-stroke to assess for the presence of these arrhythmias may contribute to an increased healthcare cost burden[3,4].

The overutilization of telemetry monitoring has been a frequent discussion regarding our nation’s ever-increasing healthcare costs. The American Board of Internal Medicine’s 2013 Choosing Wisely campaign emphasized avoiding inappropriate continuous use of telemetry monitoring in an attempt to decrease the cost of care and number of false positive errors which could negatively impact patient care[5]. In 2004, the American Heart Association (AHA) first issued a statement on telemetry monitoring indications in intensive care settings[3]. Since then, updated recommendations in 2017 have been published by the AHA in order to address the overuse of arrhythmia monitoring as well as other issues. The AHA recommends monitoring arrhythmias for 24-48 h after a stroke[6]. Dhillon *et al*[7] formulated inclusion and exclusion guidelines for which patients should need telemetry monitoring outside of the intensive care unit in an effort to decrease costs from overuse. The efficacy of these guidelines was tested in a retrospective study of 562 patients and found that no patient that was not indicated for telemetry had a clinically significant arrhythmia. This suggests that it is possible to narrow the indications for which patients should be on telemetry monitoring.

As atrial fibrillation is a common etiology of CVA/TIA, CHA2DS2-VASc is a clinical scoring tool used to evaluate the one-year risk of having a thromboembolic event in a non-anticoagulated patient with nonvalvular atrial fibrillation[8,9]. This clinical scoring tool uses age, sex, congestive heart failure, hypertension, thromboembolism history, vascular disease, and diabetes as risk factors, and assigns points to each risk factor. If the total score is greater than or equal to 2 points, current literature states that an oral anticoagulation strategy should be employed to reduce the annual risk of stroke[10]. In our study, we sought to evaluate if CHA2DS2-VASc scoring could be used to risk stratify patients with a possible diagnosis of CVA or TIA into telemetry monitoring indicated *vs* nonindicated group.

**MATERIALS AND METHODS**

A retrospective cohort study was performed at a tertiary-care safety-net community hospital between January 2014 and December 2016 with a total of 257 consecutive patients admitted with suspected CVA or TIA. Criteria for patient inclusion in the study was an admission diagnosis of CVA or TIA, lack of pre-existing atrial fibrillation, and admission with telemetry monitoring employed. Telemetry monitoring was performed for at least 24 h, consistent with current standards of care. CVA or TIA was confirmed *via* current diagnostic guidelines (including patient evaluation by the neurology consulting service and/or non-invasive brain imaging studies). The CHA2DS2-VASc score was calculated for each patient. Independent variable *t*-tests were performed using SPSS Statistics, version 16.0, when comparing patients with and without a final diagnosis of CVA or TIA.

**RESULTS**

The demographics of our study population can be seen in Table 1 and includes age, ethnicity, sex, body mass index, smoking, and history of dyslipidemia. Of the 257 patients included in our study, 75.5% (*n* = 194) patients had a confirmed ischemic event (CVA or TIA). Of these patients, only 2.3% (*n* = 6) were found to have atrial fibrillation or atrial flutter during their inpatient telemetry monitoring.

The mean and median CHA2DS2-VASc scores were found to be significantly different between patients that did and did not have a confirmed CVA/TIA (Table 2). The mean CHA2DS2-VASc score was higher in the group with confirmed CVA/TIA than in the group without an ischemic event (3.59 *vs* 2.61, *P* < 0.001). The median score was also found to be higher, with median score of 4 in patients with CVA/TIA compared to median score of 2 in patients without an event (*P* < 0.001).

**DISCUSSION**

Atrial fibrillation affects over 5 million people in the United States and increases the risk of stroke by 5-fold compared to the rest of the population[10,11]. The initial presentation of atrial fibrillation can be asymptomatic or subclinical[12]. The economic burden of people with previously unknown and asymptotic atrial fibrillation is estimated to be over 3 billion dollars[13,14]. Of those with atrial fibrillation, female sex is an established risk factor for stroke, cognitive dysfunction, and dementia[15-17]. Patients diagnosed with atrial fibrillation with a concerning CHA2DS2-VASc score should be treated with anticoagulation therapy to avoid major adverse cardiac and cerebrovascular events (MACCE). The AFIRE trial showed a temporal association between major bleeding and MACCE events, demonstrating the importance of optimal antithrombotic therapy and managing bleeding risk in patients with atrial fibrillation and stable coronary artery disease[18]. Direct oral anticoagulants are shown to be at least as efficacious and safe as warfarin among patients with non-valvular atrial fibrillation[19]. DOACs are shown to have lower MACE rates *vs* warfarin[20].

The CHA2DS2-VASc scoring tool has been validated to estimate the patient’s stroke risk with atrial fibrillation[21,22]. Limited research has been done to demonstrate its utility in predicting the risk of ischemic stroke in patients without atrial fibrillation. Our findings show that there is a statistically significant increase in the CHA2DS2-VASc score for patients with a confirmed ischemic event (3.59 *vs* 2.61, *P* < 0.001). Patients with ischemic events had their CHA2DS2-VASc score clustered on the higher end of the scores. Similarly, those patients without an ischemic event had their scores clustered towards the lower end of the score.

Of the 75.5% (*n* = 193) of patients that had a confirmed CVA/TIA, only 2.3% (*n* = 6) of these were found to have newly diagnosed atrial fibrillation. In a 2016 meta-analysis, Demeestere *et al*[23], detected atrial fibrillation in only 2.2% of patients with large-vessel CVA, and 2.4% of patients with small-vessel CVA. Moreover, a 2016 meta-analysis by Korompoki *et al*[24], found that atrial fibrillation was detected in 4% of patients post-TIA. These detection rates increased over time with an increased duration of monitoring. A meta-analysis of 32 studies showed the atrial fibrillation detection after CVA/TIA was better detected with more prolonged periods of monitoring compared to standard telemetry[25]. A study conducted by Simova *et al*[1] showed ECG telemonitoring after cryptogenic stroke or TIA only resulted in detection of AF in 10 of 36 patients (27%). The therapeutic implication of this finding suggests the benefit of routine prolonged ECG monitoring in this group as opposed to short-duration (24-48 h) inpatient telemetry.

The yield of telemetry use in this patient population is low, despite atrial fibrillation being a common cause of CVA/TIA. This presents a possible area in which we can safely reduce the amount of telemetry monitoring to only 24 h while inpatient or even possibly forgo monitoring completely in very low risk patients. Given the burden atrial fibrillation has on the general population, novel methods of screening are available and can be more cost effective[26]. Employment of wearable wireless continuous electrocardiographic (EKG) patches allows for one-to-two-week telemetry monitoring compared to the traditional 24–48-h Holter monitoring. This patient friendly approach can transmit telemetry recordings to health care providers for real time detection of cardiac events[27]. Studies have shown that the adhesive patch monitors detect more events than the conventional Holter monitor[28]. Recent developments have shown that wearables, such as smart watches, are an effective method of screening for atrial fibrillation in the general population. The Apple Heart Study used the Apple Watch in concurrent use with the current standard of diagnosing paroxysmal arrhythmias, the EKG patch, and showed that the positive predictive value of the tachograms was 0.71 (95%CI: 0.76-0.92)[29]. In addition to smart watches, portable single lead EKGs and phone applications can also be used to record palpitation events[26]. The Kardia Band designed by AliveCor mimics lead I and was designed to be used as an accessory for the Apple Watch. It was able to correctly detect atrial fibrillation with a sensitivity of 93% (95%CI: 86%-99%) and an 84% specificity (95%CI: 73%-95%)[30]. The Cardio Rhythm app for the iPhone uses the phone’s camera to act as a light sensor in order to obtain heart rate measurements. The app is not used for continuous rhythm monitoring but can be used for sporadic heart rate checks or during symptoms of palpitations. It was able to detect atrial fibrillation with a sensitivity of 92.9% (95%CI: 77%-99%) and a specificity of 97.7% (95%CI: 97%-99%)[31]. Significant gaps of knowledge remain regarding the optimal length and yield of long-term inpatient monitoring beyond the recommended 24-h inpatient telemetry monitoring[32]. Future research should be done to evaluate the percentage of detected atrial fibrillation in patients with confirmed ischemic events with outpatient cardiac rhythm monitoring of different lengths of time.

A total of 24.5% (*n* = 63) of patients in this study that were placed on telemetry monitoring for suspected CVA/TIA did not have a confirmed ischemic event per neurology evaluation. Given that the use of telemetry requires additional staff and hospital resources, increased cost burden, and is a limited resource in hospitals, efforts should be made to limit its use. Our findings suggest that the CHA2DS2-VASc score may be a valuable scoring tool to help risk stratify patients at risk for CVA/TIA and could thereby reduce the need of inpatient telemetry monitoring in patients suspected to have a CVA/TIA that have a low CHA2DS2-VASc score. Our study was limited by the small sample size of the study group. Additional studies with a larger sample size would allow for more statistical analysis of the utility of CHA2DS2-VASc in predicting CVA/TIA. Risk stratifications of patients can help reduce the use of unnecessary telemetry monitoring, especially in resource-limited hospitals.

**CONCLUSION**

Inpatient telemetry monitoring can be a costly resource in hospitals. Inappropriate use of this clinical tool only increases burgeoning healthcare costs both to the patient and the hospital. Atrial fibrillation is a risk factor for stroke which is why telemetry is indicated for 24-48 h after a CVA. However, telemetry for all patients for this short period of time can be superfluous and costly. Our study shows telemetry can be better utilized in patients with higher risk factors for atrial fibrillation as seen with higher CHA2DS2-VASc scores, and this stratification of use of telemetry monitoring will allow appropriate allocation and use for patients in whom benefit will be derived.

**ARTICLE HIGHLIGHTS**

***Research background***

Non-intensive-care inpatient telemetry monitoring is a widely used observation tool in cardiovascular medicine.

***Research motivation***

Inpatient telemetry heart rhythm monitoring overuse has been linked to higher healthcare costs.

***Research objectives***

Our study aimed to evaluate if CHA2DS2-VASc score could be used to indicate if a patient admitted with possible cerebrovascular accident (CVA) or transient ischemic attack (TIA) requires inpatient telemetry monitoring.

***Research methods***

A retrospective cohort study was performed at a tertiary-care safety-net community hospital between January 2014 and December 2016 with a total of 257 consecutive patients admitted with suspected CVA or TIA. Telemetry monitoring was performed for at least 24 h, consistent with current standards of care. CVA or TIA was confirmed *via* current diagnostic guidelines (including patient evaluation by the neurology consulting service and/or non-invasive brain imaging studies). The CHA2DS2-VASc score was calculated for each patient. Independent variable *t*-tests were performed using SPSS Statistics, version 16.0, when comparing patients with and without a final diagnosis of CVA or TIA.

***Research results***

Individuals with a confirmed CVA/TIA had a statistically significant higher CHA2DS2-VASc score compared to individuals without an ischemic event (3.59 *vs* 2.61, *P* < 0.001).

***Research conclusions***

Given the low percentage of inpatient arrhythmias identified, further research should focus on discretionary use of inpatient telemetry on higher risk patients to diagnose the arrhythmias commonly leading to CVA/TIA.

***Research perspectives***

A prospective study assessing event rate of CVA/TIA in patients with higher CHA2DS2-VASc score should be performed to validate the CHA2DS2-VASc score as a possible risk stratifying tool for patients at risk for CVA/TIA.

**REFERENCES**

1 **Simova I,** Mateev H, Katova T, Haralanov L, Dimitrov N. Telemonitoring Boosts Atrial Fibrillation Detection in Cryptogenic Stroke Patients – Preliminary Findings. *Cardiol Angiol An Int J* 2013; **1:** 47-57 [DOI: 10.9734/CA/2013/6802]

2 **Powers WJ**, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, Jauch EC, Kidwell CS, Leslie-Mazwi TM, Ovbiagele B, Scott PA, Sheth KN, Southerland AM, Summers DV, Tirschwell DL. "2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association." stroke 49.3 (2018): e46-e99 [DOI: 10.1161/STR.0000000000000163]

3 **Drew BJ**, Califf RM, Funk M, Kaufman ES, Krucoff MW, Laks MM, Macfarlane PW, Sommargren C, Swiryn S, Van Hare GF; American Heart Association; Councils on Cardiovascular Nursing, Clinical Cardiology, and Cardiovascular Disease in the Young. Practice standards for electrocardiographic monitoring in hospital settings: an American Heart Association scientific statement from the Councils on Cardiovascular Nursing, Clinical Cardiology, and Cardiovascular Disease in the Young: endorsed by the International Society of Computerized Electrocardiology and the American Association of Critical-Care Nurses. *Circulation* 2004; **110**: 2721-2746 [PMID: 15505110 DOI: 10.1161/01.CIR.0000145144.56673.59]

4 **Benjamin EM**, Klugman RA, Luckmann R, Fairchild DG, Abookire SA. Impact of cardiac telemetry on patient safety and cost. *Am J Manag Care* 2013; **19**: e225-e232 [PMID: 23844751]

5 **Brug AM**, Hudson KM, Moore R, Chakraborti C. Choosing Telemetry Wisely: a Survey of Awareness and Physician Decision-Making Regarding AHA Telemetry Practice Standards. *J Gen Intern Med* 2019; **34**: 496-497 [PMID: 30543018 DOI: 10.1007/s11606-018-4769-z]

6 **Sandau KE**, Funk M, Auerbach A, Barsness GW, Blum K, Cvach M, Lampert R, May JL, McDaniel GM, Perez MV, Sendelbach S, Sommargren CE, Wang PJ; American Heart Association Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; and Council on Cardiovascular Disease in the Young. Update to Practice Standards for Electrocardiographic Monitoring in Hospital Settings: A Scientific Statement From the American Heart Association. *Circulation* 2017; **136**: e273-e344 [PMID: 28974521 DOI: 10.1161/CIR.0000000000000527]

7 **Dhillon SK**, Rachko M, Hanon S, Schweitzer P, Bergmann SR. Telemetry monitoring guidelines for efficient and safe delivery of cardiac rhythm monitoring to noncritical hospital inpatients. *Crit Pathw Cardiol* 2009; **8**: 125-126 [PMID: 19726933 DOI: 10.1097/HPC.0b013e3181b6ef41]

8 **Chads 2 score.** CHADS 2 score | Learn the Heart. Accessed February 19, 2022. Available from: https://www.healio.com/cardiology/Learn-the-heart/cardiology-review/topic-reviews/chads-2-score

9 **Lane DA**, Lip GY. Use of the CHA(2)DS(2)-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation. *Circulation* 2012; **126**: 860-865 [PMID: 22891166 DOI: 10.1161/CIRCULATIONAHA.111.060061]

10 **Wolf PA**, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. *Stroke* 1991; **22**: 983-988 [PMID: 1866765 DOI: 10.1161/01.STR.22.8.983]

11 **Miyasaka Y**, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB, Tsang TS. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. *Circulation* 2006; **114**: 119-125 [PMID: 16818816 DOI: 10.1161/CIRCULATIONAHA.105.595140]

12 **Lin HJ**, Wolf PA, Benjamin EJ, Belanger AJ, D'Agostino RB. Newly diagnosed atrial fibrillation and acute stroke. The Framingham Study. *Stroke* 1995; **26**: 1527-1530 [PMID: 7660392 DOI: 10.1161/01.STR.26.9.1527]

13 **Turakhia MP**, Shafrin J, Bognar K, Trocio J, Abdulsattar Y, Wiederkehr D, Goldman DP. Estimated prevalence of undiagnosed atrial fibrillation in the United States. *PLoS One* 2018; **13**: e0195088 [PMID: 29649277 DOI: 10.1371/journal.pone.0195088]

14 **Turakhia MP**, Shafrin J, Bognar K, Goldman DP, Mendys PM, Abdulsattar Y, Wiederkehr D, Trocio J. Economic Burden of Undiagnosed Nonvalvular Atrial Fibrillation in the United States. *Am J Cardiol* 2015; **116**: 733-739 [PMID: 26138378 DOI: 10.1016/j.amjcard.2015.05.045]

15 **Kostopoulou A**, Zeljko HM, Bogossian H, Ciudin R, Costa F, Heijman J, Kochhaeuser S, Manola S, Scherr D, Sohal M, Wakili R, Wolf M, Irfan G; on the behalf of the DAS-CAM participants-2017-2018. Atrial fibrillation-related stroke in women: Evidence and inequalities in epidemiology, mechanisms, clinical presentation, and management. *Clin Cardiol* 2020; **43**: 14-23 [PMID: 31691981 DOI: 10.1002/clc.23284]

16 **Batta A**, Sharma YP, Hatwal J, Panda P, Kumar BGV, Bhogal S. Predictors of dementia amongst newly diagnosed non-valvular atrial fibrillation patients. *Indian Heart J* 2022; **74:** 505-509 [PMID: 36462552 DOI: 10.1016/j.ihj.2022.11.009]

17 **Chen YL**, Chen J, Wang HT, Chang YT, Chong SZ, Hsueh S, Chung CM, Lin YS. Sex Difference in the Risk of Dementia in Patients with Atrial Fibrillation. *Diagnostics (Basel)* 2021; **11** [PMID: 33922776 DOI: 10.3390/diagnostics11050760]

18 **Kaikita K**, Yasuda S, Akao M, Ako J, Matoba T, Nakamura M, Miyauchi K, Hagiwara N, Kimura K, Hirayama A, Matsui K, Ogawa H. Bleeding and Subsequent Cardiovascular Events and Death in Atrial Fibrillation With Stable Coronary Artery Disease: Insights From the AFIRE Trial. *Circ Cardiovasc Interv* 2021; **14**: e010476 [PMID: 34474583 DOI: 10.1161/CIRCINTERVENTIONS.120.010476]

19 **Ruff CT**, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. *Lancet* 2014; **383**: 955-962 [PMID: 24315724 DOI: 10.1016/S0140-6736(13)62343-0]

20 **Amin A**, Garcia Reeves AB, Li X, Dhamane A, Luo X, Di Fusco M, Nadkarni A, Friend K, Rosenblatt L, Mardekian J, Pan X, Yuce H, Keshishian A. Effectiveness and safety of oral anticoagulants in older adults with non-valvular atrial fibrillation and heart failure. *PLoS One* 2019; **14**: e0213614 [PMID: 30908512 DOI: 10.1371/journal.pone.0213614]

21 **Olesen JB**, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, Selmer C, Ahlehoff O, Olsen AM, Gislason GH, Torp-Pedersen C. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. *BMJ* 2011; **342**: d124 [PMID: 21282258 DOI: 10.1136/bmj.d124]

22 **Polenz GF**, Leiria TL, Essebag V, Kruse ML, Pires LM, Nogueira TB, Guimarães RB, Santanna RT, DE Lima GG. CHA2 DS2 VASc Score as a Predictor of Cardiovascular Events in Ambulatory Patients without Atrial Fibrillation. *Pacing Clin Electrophysiol* 2015; **38**: 1412-1417 [PMID: 26310935 DOI: 10.1111/pace.12744]

23 **Demeestere J**, Fieuws S, Lansberg MG, Lemmens R. Detection of Atrial Fibrillation Among Patients With Stroke Due to Large or Small Vessel Disease: A Meta-Analysis. *J Am Heart Assoc* 2016; **5** [PMID: 27671319 DOI: 10.1161/JAHA.116.004151]

24 **Korompoki E**, Del Giudice A, Hillmann S, Malzahn U, Gladstone DJ, Heuschmann P, Veltkamp R. Cardiac monitoring for detection of atrial fibrillation after TIA: A systematic review and meta-analysis. *Int J Stroke* 2017; **12**: 33-45 [PMID: 27681890 DOI: 10.1177/1747493016669885]

25 **Kishore A**, Vail A, Majid A, Dawson J, Lees KR, Tyrrell PJ, Smith CJ. Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. *Stroke* 2014; **45**: 520-526 [PMID: 24385275 DOI: 10.1161/STROKEAHA.113.003433]

26 **Raja JM**, Elsakr C, Roman S, Cave B, Pour-Ghaz I, Nanda A, Maturana M, Khouzam RN. Apple Watch, Wearables, and Heart Rhythm: where do we stand? *Ann Transl Med* 2019; **7**: 417 [PMID: 31660316 DOI: 10.21037/atm.2019.06.79]

27 Verrier RL, Nearing BD, Pang TD, Schachter SC. "Monitoring risk for sudden cardiac death: is there a role for EKG patches?." *Curr Opin Biomed Eng* 2019; **11:** 117-123 [DOI: 10.1016/j.cobme.2019.09.001]

28 **Barrett PM**, Komatireddy R, Haaser S, Topol S, Sheard J, Encinas J, Fought AJ, Topol EJ. Comparison of 24-hour Holter monitoring with 14-day novel adhesive patch electrocardiographic monitoring. *Am J Med* 2014; **127**: 95.e11-95.e17 [PMID: 24384108 DOI: 10.1016/j.amjmed.2013.10.003]

29 **Turakhia MP**, Desai M, Hedlin H, Rajmane A, Talati N, Ferris T, Desai S, Nag D, Patel M, Kowey P, Rumsfeld JS, Russo AM, Hills MT, Granger CB, Mahaffey KW, Perez MV. Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: The Apple Heart Study. *Am Heart J* 2019; **207**: 66-75 [PMID: 30392584 DOI: 10.1016/j.ahj.2018.09.002]

30 **Bumgarner J,** Lambert C, Cantillon D, Baranowski B, Wolski K, Hussein A, Wazni O, Lindsay B, Tarakji K. Assessing The Accuracy Of An Automated Atrial Fibrillation Detection Algorithm Using Novel Smartwatch Technology Among Patients Presenting For Elective Cardioversion. *JACC* 2018; **71:** A411 [DOI: 10.1016/S0735-1097(18)30952-5]

31 **Chan PH**, Wong CK, Poh YC, Pun L, Leung WW, Wong YF, Wong MM, Poh MZ, Chu DW, Siu CW. Diagnostic Performance of a Smartphone-Based Photoplethysmographic Application for Atrial Fibrillation Screening in a Primary Care Setting. *J Am Heart Assoc* 2016; **5** [PMID: 27444506 DOI: 10.1161/JAHA.116.003428]

32 **Sposato LA**, Cipriano LE, Saposnik G, Ruíz Vargas E, Riccio PM, Hachinski V. Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. *Lancet Neurol* 2015; **14**: 377-387 [PMID: 25748102 DOI: 10.1016/S1474-4422(15)70027-X]

**Footnotes**

**Institutional review board statement:** The study was reviewed and approved by our institutional review board (IRB) as an expedited study (IRB#16-093).

**Informed consent statement:** This research was a retrospective anonymized evaluation and informed consent was not required for IRB approval of this expedited study. The information was recorded by the investigator in such a manner that subjects cannot be identified, directly or through identifiers linked to the subjects. Our IRB approval document is provided separately.

**Conflict-of-interest statement:** Authors of no conflict of interest to disclose.

**Data sharing statement:** Technical appendix, statistical code, and dataset available from the corresponding author at amakaryu@numc.edu

**STROBE statement:** **The authors have read the STROBE Statement – checklist of items, and the manuscript was prepared and revised according to the STROBE Statement – checklist of items.**

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** September 26, 2022

**First decision:** December 19, 2022

**Article in press:**

**Specialty type:** Cardiac and cardiovascular systems

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Batta A, India; Jain S, India **S-Editor:** Liu JH **L-Editor:** A **P-Editor:** Liu JH

**Table 1 Demographics of the study population, *n* (%)**

|  |  |  |
| --- | --- | --- |
| **Variable** | **Confirmed CVA/TIA (*n* = 194)** | **Absent CVA/TIA (*n* = 63)** |
| mean age (yr) | 67.54 | 58.54 |
| *Ethnicity* |  |  |
| White | 105 (54.12) | 32 (50.79) |
| Black | 70 (36.08) | 22 (34.92) |
| Other | 19 (9.80) | 9 (14.29) |
| *Gender* |  |  |
| Men | 93 (47.94) | 24 (38.10) |
| Women | 101 (52.06) | 39 (61.90) |
| mean BMI | 27.36 | 29.10 |
| Dyslipidemia | 108 (55.70) | 22 (34.90) |
| Smoking | 54 (27.83) | 14 (22.20) |

CVA: Cerebrovascular accident; BMI: Body mass index; TIA: Transient ischemic attack.

**Table 2 CHA2DS2-Vasc scores of patients with confirmed cerebrovascular accident/transient ischemic attack *vs* absent cerebrovascular accident /transient ischemic attack, *n* (%)**

|  |  |  |
| --- | --- | --- |
| **CHA2DS2-Vasc**  | **Confirmed CVA/TIA (*n* = 194)** | **Absent CVA/TIA (*n* = 63)** |
| 0 | 11 (5.70) | 4 (6.35) |
| 1 | 26 (13.40) | 19 (30.16) |
| 2 | 24 (12.37) | 10 (15.87) |
| 3 | 29 (14.95) | 15 (23.81) |
| 4 | 42 (21.65) | 4 (6.35) |
| 5 | 26 (13.40) | 4 (6.35) |
| 6 | 20 (10.31) | 4 (6.35) |
| 7 | 11 (5.67) | 3 (4.76) |
| 8 | 5 (2.55) | 0 (0.00) |
| Mean | 3.59 | 2.61a |
| Median | 4 | 2a |

a*P* value < 0.001 on Mann-Whitney *U* Test. CVA: Cerebrovascular accident; TIA: Transient ischemic attack.